Health Care·Biotechnology·$5.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.75 | N/A | -28.64% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.75 | N/A | -28.64% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about the current financial outlook. They did not provide any updates on future guidance, indicating uncertainty.
Management did not provide specific revenue guidance for the upcoming quarters.
The company acknowledged challenges in achieving profitability.
PTC Therapeutics reported a larger-than-expected loss for the quarter, which contributed to a 1.33% decline in stock price. The lack of revenue figures and guidance adds to investor uncertainty. The management's cautious tone suggests that the company may face ongoing challenges in the near term.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ICAHN ENTERPRISES L
Mar 3, 2014